BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ANI Pharmaceuticals\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies ANI Pharmaceuticals\, Inc.'s drug
 s run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06380751-8888@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20291218
DTEND;VALUE=DATE:20291219
SUMMARY:Anastrozole: Phase 3 readout est. (NCT06380751)
DESCRIPTION:Anastrozole\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy\, Com
 pared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in
  HR-Positive\, HER2-Negative (IHC 0\, 1+\, 2+/ ISH Non-amplified)\, BRCA1\
 , BRCA2\, or PALB2m Advanced Breast Cancer\nEstimated primary completion: 
 18 December 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ana
 strozole#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06380751
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
